Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of Hydroxychloroquine
Gwendoline Ragonnet, Elisabeth Jouve, Lionel Velly, Marc Leone, Gary Duclos, Jeremy Bourenne, Karim Harti Souab, Caroline Solas, Romain Guilhaumou
Future Pharmacology, doi:10.3390/futurepharmacol2010007
During the SARS-CoV-2 pandemic, hydroxychloroquine (HCQ), was among the first drugs to be tested due to demonstrated in vitro antiviral activity against SARS-CoV-2. Pharmacokinetic variability was expected due to the frequent comorbidities and pathophysiological modifications observed in severe COVID-19 patients hospitalized in intensive care units (ICUs). The aim of this study was to describe HCQ plasmatic concentrations in ICUs and assess variability factors. A multicentric retrospective study was carried in four ICUs in Marseille from March to April 2020. There were two dosing regimens: 400 mg after a 400 mg loading dose (DR1); and 600 mg without a loading dose (DR2). HCQ concentrations were determined every 2 or 3 days. The impacts of demo-graphic, biological, and clinical covariates were investigated. The median HCQ concentration was: 0.096 mg/L on day (D) 2, 0.129 mg/L on D3 to D5, 0.140 mg/L on D6 to D10 for DR1 versus 0.116 mg/L, 0.261 mg/L, and 0.30 mg/L, respectively, for DR2. At D2, 53.9% and 46.2% of patients with DR1 and DR2, respectively, presented HCQP concentrations <0.1 µg/mL and 48.2% versus 10.7% at D3 to D5. Time post-initiation, dosing regimen, nasogastric administration, and weight showed significant association with HCQ variability. The high proportion of suboptimal HCQ concentrations can be explained by a lack of optimized dosing regimen and numerous pathophysiological changes in the COVID-19/ICU population.
References
Abdul-Aziz, Alffenaar, Bassetti, Bracht, Dimopoulos et al., Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper, Intensive Care Med,
doi:10.1007/s00134-020-06050-1Abdulaziz, Shah, Mccune, Hydroxychloroquine: Balancing the need to maintain therapeutic levels with ocular safety: An update, Curr. Opin. Rheumatol,
doi:10.1097/BOR.0000000000000500Alarcón, Mcgwin, Bertoli, Fessler, Calvo-Alén et al., Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L), Ann. Rheum. Dis,
doi:10.1136/ard.2006.068676Cunha, Alexander, Ashby, Lee, Chusney et al., Hydroxycloroquine blood concentration in lupus nephritis: A determinant of disease outcome?, Nephrol. Dial. Transplant,
doi:10.1093/ndt/gfx318Doudka, Giocanti, Basso, Ugdonne, Barthelemy et al., Development and validation of a simple and rapid UHPLC-MS/MS method for the quantification of hydroxychloroquine in plasma and blood samples in the emergency context of SARS-CoV-2 pandemic, Ther. Drug Monit,
doi:10.1097/FTD.0000000000000836Fan, Ma, Chen, Yang, Cheng et al., Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS, Rheumatol. Ther,
doi:10.1007/s40744-015-0012-0Gagnieu, Garraffo, Solas, Peytavin, Guilhaumou et al., Recommandations pour le Suivi Thérapeutique Pharmacologique du lopinavir/r et de l'hydroxychloroquine chez les patients traités pour une infection à SARS-CoV-2 (COVID-19
Gautier-Veyret, Truffot, Bailly, Fonrose, Thiebaut-Bertrand et al., Inflammation is a potential risk factor of voriconazole overdose in hematological patients, Fundam. Clin. Pharm,
doi:10.1111/fcp.12422Giaime, Guenoun, Pedinielli, Narbonne, Bergounioux et al., Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection, Nephrol. Dial. Transplant,
doi:10.1093/ndt/gfaa191Kivity, Landevitz, Shoenfeld, Ben-Zvi, Hydroxychloroquine: From malaria to autoimmunity, Clin. Rev. Allergy Immunol,
doi:10.1007/s12016-010-8243-xLagier, Million, Gautret, Colsona, Cortaredonaa et al., Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med. Infect. Dis,
doi:10.1016/j.tmaid.2020.101791Lê, Peiffer-Smadja, Guedj, Néant, Mentré et al., Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial, J. Antimicrob. Chemotherpy,
doi:10.1093/jac/dkaa191Mahévas, Tran, Roumier, Chabrol, Paule et al., Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: Observational comparative study using routine care data, Br. Med. J,
doi:10.1136/bmj.m1844Marzolini, Stader, Stoeckle, Franzeck, Egli et al., Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations, Antimicrob. Agents Chemother,
doi:10.1128/AAC.01177-20Morita, Takahashi, Yoshida, Yokota, Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus, Ther. Drug Monit,
doi:10.1097/FTD.0000000000000261Oberoi, Zhao, Sidhu, Viani, Trinh et al., A Phase 1 Study to Evaluate the Effect of Crushing, Cutting Into Half, or Grinding of Glecaprevir/Pibrentasvir Tablets on Exposures in Healthy Subjects, J. Pharm. Sci
Petri, Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibodypositive patients, Curr. Rheumatol. Rep,
doi:10.1007/s11926-010-0141-yRainsford, Parke, Clifford-Rashotte, Kean, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology,
doi:10.1007/s10787-015-0239-yRoustit, Guilhaumou, Molimard, Drici, Laporte et al., Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence, Therapies,
doi:10.1016/j.therap.2020.05.010Smit, Peeters, Van Den Anker, Knibbe, Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties, Clin. Pharmacokinet,
doi:10.1007/s40262-020-00891-1Thémans, Belkhir, Dauby, Yombi, De Greef et al., Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization, Eur. J. Drug Metab. Pharmacokinet,
doi:10.1007/s13318-020-00648-yVenisse, Peytavin, Bouchet, Gagnieu, Garrafo et al., Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection, Antivir. Res,
doi:10.1016/j.antiviral.2020.104866Wu, Chen, Cai, Xia, Xing et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern. Med,
doi:10.1001/jamainternmed.2020.0994Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am,
doi:10.1093/cid/ciaa237Yasu, Konuma, Kato, Kurokawa, Takahashi et al., Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients, Leuk. Lymphoma,
doi:10.1080/10428194.2017.1300897Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet
{ 'indexed': {'date-parts': [[2022, 3, 28]], 'date-time': '2022-03-28T23:37:41Z', 'timestamp': 1648510661441},
'reference-count': 28,
'publisher': 'MDPI AG',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2022, 3, 19]],
'date-time': '2022-03-19T00:00:00Z',
'timestamp': 1647648000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['Future Pharmacology'],
'abstract': '<jats:p>During the SARS-CoV-2 pandemic, hydroxychloroquine (HCQ), was among the first drugs '
'to be tested due to demonstrated in vitro antiviral activity against SARS-CoV-2. '
'Pharmacokinetic variability was expected due to the frequent comorbidities and '
'pathophysiological modifications observed in severe COVID-19 patients hospitalized in '
'intensive care units (ICUs). The aim of this study was to describe HCQ plasmatic '
'concentrations in ICUs and assess variability factors. A multicentric retrospective study was '
'carried in four ICUs in Marseille from March to April 2020. There were two dosing regimens: '
'400 mg after a 400 mg loading dose (DR1); and 600 mg without a loading dose (DR2). HCQ '
'concentrations were determined every 2 or 3 days. The impacts of demo-graphic, biological, '
'and clinical covariates were investigated. The median HCQ concentration was: 0.096 mg/L on '
'day (D) 2, 0.129 mg/L on D3 to D5, 0.140 mg/L on D6 to D10 for DR1 versus 0.116 mg/L, 0.261 '
'mg/L, and 0.30 mg/L, respectively, for DR2. At D2, 53.9% and 46.2% of patients with DR1 and '
'DR2, respectively, presented HCQP concentrations <0.1µg/mL and 48.2% versus 10.7% at D3 to '
'D5. Time post-initiation, dosing regimen, nasogastric administration, and weight showed '
'significant association with HCQ variability. The high proportion of suboptimal HCQ '
'concentrations can be explained by a lack of optimized dosing regimen and numerous '
'pathophysiological changes in the COVID-19/ICU population.</jats:p>',
'DOI': '10.3390/futurepharmacol2010007',
'type': 'journal-article',
'created': {'date-parts': [[2022, 3, 21]], 'date-time': '2022-03-21T01:26:22Z', 'timestamp': 1647825982000},
'page': '92-98',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': [ 'Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The '
'Illustration of Hydroxychloroquine'],
'prefix': '10.3390',
'volume': '2',
'author': [ {'given': 'Gwendoline', 'family': 'Ragonnet', 'sequence': 'first', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-4873-6522',
'authenticated-orcid': False,
'given': 'Elisabeth',
'family': 'Jouve',
'sequence': 'additional',
'affiliation': []},
{'given': 'Lionel', 'family': 'Velly', 'sequence': 'additional', 'affiliation': []},
{'given': 'Marc', 'family': 'Leone', 'sequence': 'additional', 'affiliation': []},
{'given': 'Gary', 'family': 'Duclos', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jeremy', 'family': 'Bourenne', 'sequence': 'additional', 'affiliation': []},
{'given': 'Karim', 'family': 'Harti Souab', 'sequence': 'additional', 'affiliation': []},
{'given': 'Caroline', 'family': 'Solas', 'sequence': 'additional', 'affiliation': []},
{'given': 'Romain', 'family': 'Guilhaumou', 'sequence': 'additional', 'affiliation': []}],
'member': '1968',
'published-online': {'date-parts': [[2022, 3, 19]]},
'reference': [ {'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104866'},
{'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11926-010-0141-y'},
{'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12016-010-8243-x'},
{'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/ard.2006.068676'},
{'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00134-020-05955-1'},
{'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00134-020-06050-1'},
{'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10787-015-0239-y'},
{'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40262-020-00891-1'},
{ 'key': 'ref9',
'unstructured': 'Recommandations pour le Suivi Thérapeutique Pharmacologique du '
'lopinavir/r et de l’hydroxychloroquine chez les patients traités pour '
'une infection à SARS-CoV-2 (COVID-19). Groupe Pharmacologie—AC43 de '
'l’ANRS et le groupe STP-PT '
'(SFPT)https://sfptfr.org/images/documents/STP/Recommandations_STP_ANRS_AC43_Pharmacologie_v2_26_03_20.pdf'},
{'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/BOR.0000000000000500'},
{'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ndt/gfx318'},
{'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa237'},
{'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.therap.2020.05.010'},
{'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/00007691-200312000-00005'},
{'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/FTD.0000000000000261'},
{'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40744-015-0012-0'},
{'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.tmaid.2020.101791'},
{'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamainternmed.2020.0994'},
{'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30566-3'},
{'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dkaa191'},
{'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.xphs.2018.02.015'},
{'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s13318-020-00648-y'},
{'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/10428194.2017.1300897'},
{'key': 'ref24', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/fcp.12422'},
{'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.01177-20'},
{'key': 'ref26', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ndt/gfaa191'},
{'key': 'ref27', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/FTD.0000000000000836'},
{'key': 'ref28', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1844'}],
'container-title': ['Future Pharmacology'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/2673-9879/2/1/7/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 3, 21]],
'date-time': '2022-03-21T02:10:56Z',
'timestamp': 1647828656000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.mdpi.com/2673-9879/2/1/7'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 3, 19]]},
'references-count': 28,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 3]]}},
'alternative-id': ['futurepharmacol2010007'],
'URL': 'http://dx.doi.org/10.3390/futurepharmacol2010007',
'relation': {},
'ISSN': ['2673-9879'],
'issn-type': [{'value': '2673-9879', 'type': 'electronic'}],
'published': {'date-parts': [[2022, 3, 19]]}}
